$0.96
+0.04 (+4.46%)
Open$0.93
Previous Close$0.92
Day High$1.02
Day Low$0.87
52W High$34.89
52W Low$0.61
Volume—
Avg Volume19.09M
Market Cap3.87M
P/E Ratio—
EPS$-24.68
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+2,204.7% upside
Current
$0.96
$0.96
Target
$22.10
$22.10
$15.13
$22.10 avg
$31.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.66M | 1.54M | 1.31M |
| Net Income | -168,962,176 | -140,814,851 | -292,011 |
| Profit Margin | -10,188.2% | -9,678.8% | -22.2% |
| EBITDA | -208,168,754 | -183,128,360 | -341,169 |
| Free Cash Flow | — | — | -173,511 |
| Rev Growth | +8.0% | +8.0% | +20.5% |
| Debt/Equity | — | — | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |